Indication
Advanced Digestive System Neuroendocrine Neoplasm
1 clinical trial
1 product
Clinical trial
A Phase 2 Trial of the CDK4/6 Inhibitor Abemaciclib in Patients With Advanced and Refractory Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs)Status: Recruiting, Estimated PCD: 2025-09-30
Product
Abemaciclib